Similarly, using a p53-null preclinical model, our group has shown that LG100268 with the SERM tamoxifen can reduce Ki-67 and cyclin D1 expression in normal mammary tissue and prevent both ER-positive and ER-negative mammary tumors (187). The gene discussed is ESR1; the disease is breast cancer.